Drug Profile
SR2F
Alternative Names: Soluble transforming growth factor-β antagonist; TGF-β receptor-human IgG fusion proteinLatest Information Update: 25 Aug 2006
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Class
- Mechanism of Action Transforming growth factor beta2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Aug 2002 Preclinical trials in Cancer in USA (unspecified route)